# Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

> **NCT07100054** · — · ENROLLING_BY_INVITATION · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 100 (estimated)

## Conditions studied

- CDK4/6 Inhibitor
- Breast Cancer
- CYP3A4 Protein, Human
- Drug Interaction
- Pharmacogenetic Testing

## Interventions

- **GENETIC:** Whole gene sequencing
- **OTHER:** Drug-drug interaction analysis
- **OTHER:** Biomarker analysis

## Key facts

- **NCT ID:** NCT07100054
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-10
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100054, "Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07100054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*